Results 171 to 180 of about 784,460 (315)

Dynamic variation in a combined inflammation-tumor marker index during neoadjuvant chemotherapy and its value for organ-preservation decisions in gastric cancer. [PDF]

Open Life Sci
Liu K, Qian H, Chen S, Zhang S, Zhao W.
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

A novel inflammation and tumor marker-based prognostic score, neutrophil-lymphocyte ratio-C-reactive protein-Ca19-9, in metastatic gastric cancer. [PDF]

Oncol Lett
Karabuğa B, Kaya OB, Karabuğa EK, Aydemir E, Yilmaz ME, Bolat ST, Uçkun A, Kaptan E, Ateş Ö, Büyükkör M.   +9 more
europepmc   +1 more source

Tumor markers and radioimmunoassay.

RADIOISOTOPES, 1984
openaire   +3 more sources

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Correction to "Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer". [PDF]

JGH Open
europepmc   +1 more source

Personalizing CA125 Levels Using Tumor Marker Variants: A Case-Control Analysis of Diagnostic Performance for Pancreatic Cancer. [PDF]

Cancer Epidemiol Biomarkers Prev
Hozaka Y, Macgregor-Das A, Hayashi M, Yoshida T, Blackford AL, Hirose K, He J, Afghani E, Canto MI, Goggins MG.   +9 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Appendiceal Adenocarcinoma Cytoreduction Outcomes and Perioperative Serum Tumor Marker Levels.

JAMA Netw Open
Pattalachinti VK, Seldomridge A, Yousef A, Yousef M, Fallon EA, McCullough J, Gunes BB, Song Y, Scally CP, Mansfield P, White MG, Fournier KF, Helmink BA, Shen JP.   +13 more
europepmc   +1 more source

Peripheral blood tumor marker levels can indicate the location of lung cancer metastasis. [PDF]

Oncol Lett
Wang J, Wang X, Mao Y, Niu H, Zhao F, Shen D, Wang L.   +6 more
europepmc   +1 more source